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Abstract
BACKGROUND: Upregulation of the endo-b-D-
glucuronidase, heparanase, was noted in an increasing
number of human malignancies. Heparanase expres-
sion correlated with enhanced local and distant meta-
static spread, increased vascular density, and reduced
postoperative survival. PATIENTS AND METHODS:
We analyzed heparanase expression in 60 patients
(aged 59 ± 17 years) with malignant salivary tumors
(39 males and 21 females) using immunohisto-
chemistry. We applied antiheparanase antibody 733,
which has previously been shown to preferentially
recognize a 50-kDa active heparanase subunit over a
65-kDa latent enzyme. Thus, immunostaining can di-
rectly be correlated with enzymatic activity. RESULTS:
Heparanase staining was positive (> 0) in 70% of tu-
mors (42 of 60 patients) and was negative (0) in the
remaining 30% (18 patients). The cumulative survival of
patients diagnosed as heparanase-negative (n = 18) at
300monthswas 70% (95%confidence interval = 35–88).
In contrast, the cumulative survival of patients diag-
nosed as heparanase-positive (n = 42) at 300 months
was 0% (statistically significant difference, P = .035).
CONCLUSIONS: Heparanase expression levels in-
versely correlate with the survival rates of salivary gland
cancer patients, clearly indicating that heparanase is
a reliable prognostic factor for this malignancy and an
attractive target for anticancer drug development.
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Introduction
The extracellular matrix (ECM) consists mainly of collagen,
proteoglycans, and glycoproteins such as laminin and fibro-
nectin; provides an essential physical barrier between cells
and tissues; and provides a scaffold for cell growth, mi-
gration, differentiation, and survival. The ECM undergoes
continuous remodeling during development and in certain
pathological conditions, such as wound healing and cancer
[1]. ECM remodeling enzymes are thus expected to profoundly
affect cell and tissue functions. Heparanase is an endoglycosi-
dase that specifically cleaves heparan sulfate (HS) side chains
of HS proteoglycans [2–4]—the major proteoglycans in the
ECM and cell surfaces. In addition to its structural role as a
molecular link between different ECM components, contributing
to ECM integrity and insolubility, HS side chains can bind a
variety of biologic mediators such as growth factors, cytokines,
and chemokines, thus forming a readily available reservoir that
can be liberated on local or systemic cues [5–9]. Traditionally,
heparanase activity was implicated in cellular invasion associ-
ated with angiogenesis, inflammation, and cancer metastasis
[10–12]. This notion recently gained further support by em-
ploying siRNA and ribosome technologies, clearly depicting
heparanase-mediated HS cleavage and ECM remodeling as
critical requisites for angiogenesis and metastatic spread [13].
More recently, heparanase upregulation was documented in
an increasing number of primary human tumors. Heparanase
upregulation correlated with reduced postoperative survival
of pancreatic [14], bladder [15], gastric [16], cervical [17], and
colorectal [17,18] cancer patients. Similarly, heparanase up-
regulation correlated with increased lymph node and distant
metastases [15,19–21], providing strong clinical support for the
prometastatic feature of heparanase.
We examined heparanase expression (Table 1) in a series
of 60 salivary gland tumor biopsies and then correlated hepa-
ranase expression with clinical and molecular parameters.
Significantly, heparanase expression in salivary gland tumors
inversely correlated with cumulative survival and disease-free
survival (DFS), suggesting that heparanase plays an impor-
tant role in the progression of this kind of cancer and can thus
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Sixty patients (39 males and 21 females aged 59 ±
17 years) with malignant salivary tumors were analyzed.
Clinical data were collected from patients’ hospitalization
and follow-up records, and included tumor type and size,
salivary gland involvement (parotid, submandibular, sub-
lingual, or minor salivary glands), and lymph node metas-
tasis (0 = negative; > 0 = positive). Twelve of the tumors
were mucoepidermoid cell carcinomas, 11 were adeno-
carcinomas, 10 were squamous cell carcinomas, 9 were
acinic cell carcinomas, 6 were adenoid cystic carcinomas, 4
were low-grade polymorphous adenocarcinomas, and 4
were anaplastic cell carcinomas. There was only one ex-
ample of each of the following: malignant oncocytoma, sali-
vary duct cell carcinoma, carcinoma ex-mixed tumor, and
neuroendocrine carcinoma. All biopsies were obtained at
the time of diagnosis. Five patients had extensive locally
spread invasion, two had distant metastasis to the lungs, and
one had distant metastasis to the brain. The immunohistologic
analysis of heparanase, P27, ErbB-2, and von Willebrand
factor (vWF) was performed on paraffin-embedded tumor
specimens, evaluated, and scored by expert pathologists.
Immunostaining
Heparanase staining The staining of formalin-fixed paraf-
fin-embedded 5-mm sections for heparanase was performed
essentially as described [22,23]. Briefly, slides were depar-
affinized with xylene and rehydrated, and endogenous per-
oxidase activity was quenched (30 minutes) by 3% hydrogen
peroxide in methanol. They were then subjected to antigen
retrieval by boiling (20minutes) in 10mMcitrate buffer (pH 6),
incubated with 10% normal goat serum (NGS) in phosphate-
buffered saline (PBS) for 60 minutes to block nonspecific
binding, and incubated (for 20 hours at 4jC) with anti–
heparanase antibody 733 diluted 1:100 in blocking solution.
Antibody 733 was raised in rabbits against a 15–amino
acid peptide (KKFKNSTYSRSSVDC) that maps at the C-
terminus of the 50-kDa heparanase subunit [22]. Slides were
then extensively washed with PBS containing 0.01% Triton
X-100 and incubated with a secondary reagent (Envision kit;
Dako, Glostrup, Denmark) according to the manufacturer’s
instructions. Following additional washes, color was devel-
oped with AEC reagent (Sigma, St. Louis, MO), and sections
were counterstained with hematoxylin and mounted as de-
scribed [22]. Slides were scored as heparanase-negative
(0) or heparanase-positive (> 0). In all tumors diagnosed as
heparanase-positive, more than 50% of cells reacted with the
antiheparanase antibody.
vWF staining of vascular endothelial cells Following depar-
affinization and rehydration, slides were treated with 0.1%
trypsin (for 20 minutes at 37jC) and washed, and antigen
retrieval was performed by boiling in 0.05% citraconic an-
hydride (pH 7.4; Sigma-Aldrich, St. Louis, MO) for 45minutes
[24]. Slides were washed, incubated with blocking solution
(10% NGS in PBS), and stained with anti-vWF antibodies
(polyclonal antibodies, diluted 1:250; Dako) using the Envi-
sion kit, as described above. vWF-positive vascular struc-
tures in three random microscopic fields were counted (in a
blind manner) at high magnification ( 40).
ErbB-2 staining Staining for ErbB-2 was performed as de-
scribed above, except that 10 mM citrate buffer (pH 6) was
used for antigen retrieval (in a 800-W microwave oven for
15minutes). Slideswere incubatedwith anti ErbB-2antibodies
(polyclonal antibodies, diluted 1:4000; Dako) for 60 minutes
at room temperature, followed by the application of the
streptavidin–biotin method (Histostain Plus; Zymed Labora-
tories, South San Francisco, CA). Positive controls were run in
parallel and included sections from a breast tumor that was
known to overexpress ErbB-2. A negative control was ob-
tained by substituting preimmune rabbit serum for primary
antibodies. Positive staining for ErbB-2 was considered when
more than 10% of tumor cells showed membranous staining.
Positive staining was scored as 1+ = weak or 2+ = strong.
Statistical Analysis
Categorical variables’ frequencies, percentages, and dis-
tribution were calculated. The distribution of categorical var-
iables was compared by chi-square analysis (large sample)
and Fisher-Irwin exact test (small sample). For continuous
variables (age and blood vessel density), the ranges, means,
standard deviations, and standard errors were calculated.
The results between the continuous variables (two sub-
groups) were compared by t-test for differences in means.
Kaplan-Meier analysiswas used to calculate the probability of
survival and DFS rates as a function of time in subgroups of
patients specified by heparanase levels. Log-rank test was
applied to perform comparisons with Kaplan-Meier analysis.
Results
Heparanase Expression in 60 Patients with Salivary
Gland Tumors
Heparanase activity has long been correlated with the
metastatic potential of tumor-derived cells [9,11,12]. Since
the cloning of the heparanase gene and the availability of
specific molecular probes, heparanase upregulation has
been documented in an increasing number of primary human
tumors bymeans of in situ hybridization and immunostaining.




> 0 42 70
Total 60 100
*0, Negative; > 0, positive (see Figure 1 for representative cases).
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Recently, we developed a polyclonal antibody (pAb 733)
that preferentially recognizes the 50-kDa heparanase subunit
of 50 + 8 active heterodimer enzyme over the latent 65-kDa
protein and used this antibody to study heparanase process-
ing, trafficking route, and cellular localization [22]. Further-
more, this antibody is suitable for the staining of paraffin
sections [22]. Thus, immunostaining of archival materials
can directly be correlated with heparanase enzymatic activity.
We employed antibody 733 to examine heparanase ex-
pression in 60 salivary gland tumor specimens. Heparanase
staining was positive (> 0) in 70% (42 patients) of tumors and
negative (0) in the remaining 30% (18 patients). All control
healthy tissues stained negatively for heparanase. Repre-
sentative photomicrographs of heparanase-negative (upper
panel ) and heparanase-positive (lower panel ) tumor biopsies
are shown in Figure 1.
Heparanase Expression according to Age, Gender,
Tumor Size, and Lymph Node Metastasis
No significant correlations were demonstrated between
the level of heparanase staining and either the age or gender
of patients. Similarly, no significant correlation was ob-
served between heparanase staining level and either the
type of tumor of the salivary gland involved (Table 2) or the
tumor size (Table 3) and lymph node metastasis. Two (11%)
of 17 patients stained negative for heparanase (0), and
8 (21%) of 38 patients diagnosed as heparanase-positive
had lymph node metastases (> 0; P = .34).
Heparanase and c-ErbB-2 Immunostaining
Fifteen (83%) of 18 salivary gland tumor specimens that
were found negative for heparanase were also negative for
ErbB-2 expression, whereas the other three (17%) cases
exhibited weak ErbB-2 staining (1+; Table 4). Similarly, the
majority (74%) of heparanase-positive cases were negative
for ErbB-2 expression (Table 4), suggesting that ErbB-2 is
not a clinical parameter for salivary gland tumors, in agree-
ment with our previous finding [25]. Interestingly, four (10%)
heparanase-positive salivary gland tumor specimens and
none of the heparanase-negative specimens exhibited high
levels of ErbB-2 staining (2+; Table 4).
Heparanase Expression Level and Blood Vessel Density
Heparanase has previously been considered as a pro-
angiogenic mediator due to its ability to release HS-bound
angiogenic growth factors, such as basic fibroblast growth
factor and vascular endothelial growth factor, sequestered in
the ECM [7,9,26]. In fact, increased vessel density correlated
with heparanase expression levels in several human tumors
[15,19,27,28]. The staining of vascular endothelial cells
with anti-vWF antibody revealed a mean of 11.5 blood ves-
sels per high-power field in heparanase-negative specimens
vs 15.3 blood vessels per high-power field in heparanase-
positive tumor specimens (Table 5). Although not statistically
significant, these results agree with the notion that hepa-
ranase functions as a proangiogenic mediator.
Heparanase and Postoperative Survival
To determine the prognostic value of heparanase in sali-
vary gland cancer, we analyzed the probability of survival and
Figure 1. Immunohistochemical staining of heparanase in patients with
salivary gland tumors. Formalin-fixed paraffin-embedded 5-m sections of
salivary gland tumors were subjected to immunostaining of heparanase,
applying antiheparanase pAb 733 as described in the Materials and Methods
section. Representative photomicrographs of heparanase-negative (upper
panel) and heparanase-positive (lower panel) stainings are shown.
Table 2. Heparanase Expression in Different Salivary Gland Tumors (P = .26).
Heparanase/Gland Patients [n (%)]
0 > 0
Parotid 11 (61) 23 (54)
Submandibular 0 7 (17)
Minor (hard palate) 2 (11) 7 (17)
Sublingual 1 (6) 1 (2)
Minor (oral) 4 (22) 4 (10)
Total 18 (100) 42 (100)
Table 3. Heparanase Levels and Tumor Size (P = .20).
Heparanase/Tumor Size Patients [n (%)]
0 > 0
1 3 (17) 16 (38)
2 8 (44) 15 (36)
3 3 (17) 1 (3)
4 3 (17) 6 (14)
ND 1 (5) 4 (9)
Total 18 (100) 42 (100)
1, < 2 cm; 2, < 4 cm; 3, < 6 cm; 4, > 6 cm.
ND, not determined.
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the DFS of patients following curative resection. The prob-
ability of survival of patients diagnosed as heparanase-
negative (n = 18) at 300 months (25 years) was 70% [95%
confidence interval (95% CI) = 35–88]. In contrast, the
probability of survival of patients found to express hepa-
ranase (n = 41) at 300monthswas 0% (statistically significant
difference, P = .05) (Figure 2). Similarly, the probability of
DFS of patients diagnosed as heparanase-negative (0; n =
18) at 300 months (25 years) was 70% (95% CI = 37–88)
(Figure 3), whereas the probability of DFS of patients
expressing heparanase (n = 41) at 300 months was 0%
(statistically significant difference, P = .035) (Figure 3). Thus,
heparanase expression levels inversely correlate with the
survival rates of salivary gland cancer patients, clearly indi-
cating that heparanase is a reliable prognostic factor for
this malignancy.
Lymph Node Metastasis and Postoperative Survival
To determine the impact of lymph node metastasis on the
survival of patients with salivary gland cancer, we analyzed
the probability of survival of patients in correlation with lymph
node metastasis. The probability of survival of patients diag-
nosed as free of lymph node metastasis (0; n = 44) was 86%
at 24 months (95% CI = 71–93) and 14% (95%CI = 6–56) at
300 months (25 years). In contrast, the probability of survival
of patients diagnosed with positive lymph node metastasis
(> 0; n = 10) was 0%at 24months and 0%at 300months. The
probability of survival of patients diagnosed with negative
lymph node metastases (0) was significantly higher than
that of patients diagnosed with positive lymph node metas-
tasis (> 0; P = .0001).
Discussion
Salivary gland neoplasms are relatively rare, accounting for
5% of tumors arising in the head and neck region. The fre-
quency of these tumors is f0.5 per 100,000; the majority
arise in the parotid gland (70%) and, of these, 25% are
malignant. Of those tumors arising in the salivary glands,
50% are malignant. Surgical resection is the primary treat-
ment for thismalignancy, whereas radiation therapy is usually
applied on patients with advanced disease. Chemotherapy
has been reserved for patients with incurable salivary neo-
plasm, with a typical response rate of 15% to 30% [29]. Given
the variability and complexity of these tumors, a better under-
standing of its basic biology is required to define relevant
targets for the development of novel therapeutic approaches.
For the first time, we examined heparanase expression in a
series of 60 salivary tumor biopsies. Heparanase upregula-
tion was noted in 70% of cases (Table 1, Figure 1), in
agreement with previous reports documenting an increased
heparanase expression in malignancies of the breast, colon,
pancreas, bladder, gastrointestinal tract, and liver [14,15,18,
20,21,27,30]. Clearly, heparanase upregulation inversely
correlates with the postoperative survival of patients with
salivary gland tumors, as indicated by probability of survival
Table 4. Heparanase and c-ErbB-2 Expression Levels (P = .037).
Heparanase/c-ErbB-2 Patients [n (%)]
0 > 0
0 15 (83) 31 (74)
1 3 (17) 1 (2)
2 0 4 (10)
ND 0 6 (14)
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Figure 2. Overall survival curves of patients with salivary gland tumors
according to heparanase immunostaining levels. Kaplan-Meier analysis showed
poor survival of patients with positive heparanase expression, compared with
patients who were diagnosed as heparanase-negative. After 300 months
(25 years) of follow-up, 0% of heparanase-positive patients survived, compared
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Figure 3. DFS curves of patients with salivary gland tumors according to
heparanase expression levels. Kaplan-Meier analysis showed significantly
poor survival in patients with positive heparanase staining, compared with
patients with negative (0) heparanase expression. After 300months (25 years)
of follow-up, 0% of patients with positive heparanase staining survived,
compared with 70% of patients with negative staining (P = .035).
Table 5. Blood Vessel Density and Heparanase Staining Levels (P = .14).
Heparanase/Blood Vessels Patients [n (%)]
0 (n = 5) > 0 (n = 17)
Range 6.0–22.0 4.7–31.0
Mean vessel density 11.5 15.3
Standard error 2.9 1.6
Sections of salivary gland tumors were stained with anti-vWF antibodies, as
described in the Materials and Methods section. vWF-positive vascular
structures in three random fields were counted (in a blind manner) at high
magnification ( 40).
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(Figure 2) and DFS (Figure 3) analyses. This finding is in
agreement with enhanced metastatic spread and reduced
postoperative survival noted for several other human cancers
overexpressing heparanase [15,16,19–21], collectively pro-
viding a strong clinical support for the prometastatic func-
tion of heparanase. The significance of heparanase as a
prognostic factor in patients with salivary gland neoplasms
is best demonstrated by the finding that the cumulative
survival of patients who express heparanase was zero.
These observations and the occurrence of a single functional
human heparanase gene [31–34] strongly suggest that
the enzyme is an attractive target for the development of
anticancer drugs. Given the unique feature of antibody 733
that preferentially recognizes the 50-kDa subunit, the staining
of tumor biopsies can directly be correlated with the enzy-
matic activity of heparanase.
Enhanced metastatic spread involves tumor blood and
lymphatic vessels. Indeed, increased microvessel density
correlated with heparanase upregulation in patients with
hepatocellular [27], bladder [15], cervical [17], and colorectal
[19] carcinomas, as well as in those with multiple myeloma
[28]. This proangiogenic feature of heparanase was re-
capitulated in several in vitro and in vivo model systems
[13,35–37]. The increase in blood vessel density observed
in heparanase-positive salivary gland carcinoma (Table 5) is
in agreement with this trend, although it was not statistically
significant, most likely due to the small number of samples
available for staining and the internal variability of the sali-
vary tumor subtypes analyzed (Table 2). These factors may
also explain the lack of significant correlation between hepa-
ranase expression and lymph node metastasis.
The upregulation of epidermal growth factor (EGF) recep-
tors, most often ErbB-1 and ErbB-2, is implicated in the
progression of several human carcinomas, and small mole-
cule inhibitors or neutralizing antibodies directed against
these receptors are successfully applied in clinics. ErbB-2,
however, was detected only in a small number of salivary
gland tumor biopsies (Table 4) and is thus not likely to play a
pivotal role in the progression of this cancer [25,29]. Interest-
ingly, 10% of salivary gland tumor biopsies that were diag-
nosed as heparanase-positive were noted to express high
levels (2+) of ErbB-2, whereas none of the heparanase-
negative specimens was diagnosed as such (Table 4). Thus,
a correlation between the expression of heparanase and
EGF receptors should better be investigated in carcinomas
where EGF receptors are clinically implicated, such as in
carcinoma of the breast. For the first time, the results dem-
onstrate heparanase induction in salivary gland tumors
and predict poor prognosis for patients who express hepa-
ranase, further emphasizing the notion that heparanase is a
valid target for the development of anticancer drugs.
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